Compare TBI & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TBI | QNCX |
|---|---|---|
| Founded | 1985 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 129.9M | 167.0M |
| IPO Year | 1995 | 2019 |
| Metric | TBI | QNCX |
|---|---|---|
| Price | $3.74 | $0.10 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 1 | 3 |
| Target Price | $6.00 | ★ $10.00 |
| AVG Volume (30 Days) | 266.0K | ★ 67.7M |
| Earning Date | 05-21-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.39 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.25 | N/A |
| Revenue Next Year | $3.90 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.44 | $0.09 |
| 52 Week High | $7.78 | $4.55 |
| Indicator | TBI | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 36.03 | 27.93 |
| Support Level | $3.44 | $0.09 |
| Resistance Level | $5.56 | $0.98 |
| Average True Range (ATR) | 0.25 | 0.02 |
| MACD | -0.00 | 0.09 |
| Stochastic Oscillator | 29.52 | 21.00 |
TrueBlue Inc is a provider of specialized workforce solutions that connect employers with talent. Its reportable segments include PeopleReady, which provides blue-collar contingent staffing and delivers on-demand and skilled labor across industries such as construction, transportation, retail, hospitality, and energy. The PeopleManagement segment offers contingent labor and outsourced industrial workforce solutions, mainly on-site at client facilities, through its OnSite and Centerline operations, focusing on workforce management and commercial driver services. PeopleSolutions delivers services focused on professional and specialized talent acquisition, as well as workforce management and compliance. The company generates the majority of its revenue from the PeopleReady segment.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.